Cumberland Pharmaceuticals (CPIX) Other Non-Current Liabilities (2010 - 2026)

Cumberland Pharmaceuticals has reported Other Non-Current Liabilities for 17 years, with the latest figure at $5.6 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 6.44% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (down 6.44% YoY) and the FY2025 annual result came in at $5.8 million, down 7.58% from the prior year.
• Other Non-Current Liabilities fell to $5.6 million in Q1 2026 per CPIX's latest filing, from $5.8 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $11.3 million in Q1 2022 and troughed at $5.6 million in Q1 2026.
• A 5-year average of $7.1 million and a median of $6.5 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities soared 44.56% in 2022, then plunged 37.38% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $7.6 million in 2022, then fell by 14.92% to $6.5 million in 2023, then declined by 2.38% to $6.3 million in 2024, then retreated by 7.58% to $5.8 million in 2025, then decreased by 3.48% to $5.6 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $5.6 million, $5.8 million, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.